- There are now data supporting the use of the Absorb everolimus-eluting bioresorbable vascular scaffold (BVS) for treating non-complex coronary lesions.
- The complete bioresorption of the scaffold after 2–3 years is an important advantage over metallic stents because there will not be a nidus for stent-related thrombotic complications.
- The safety and efficacy of BVS has yet to be determined in patients with coronary bifurcation lesions
Catheter Cardiovasc Interv. 2016 Nov 15;88(6):870-871.